Ex vivo proliferation assays for CLL patient samples:
optimal for BTK or PI3Kδ inhibitors
optimal for BTK or PI3Kδ inhibitors
Vivia Biotech has developed accurate assays specifically
tailored for characterizing the ex vivo pharmacological profile of your antiproliferative CLL drug compounds, directly using authentic patient samples.
Vivia Biotech can enhance your CLL drug profiling processes by utilizing advanced assays employing state-of-the-art assays in a native environment, and gaining access to real biological samples from patients, thereby identifying the most effective drugs for CLL treatment.
CLL Patient Samples Availability & Clinical Data Associated
Vivia CLL proliferation assays
To faithfully replicate the intricate in vivo microenvironment of CLL, we have formulated an ex vivo assay that optimally supports CLL proliferation and viability. This method utilizes a complete native peripheral blood or bone marrow CLL sample, combined with CpG + IL-2 + HS5 stromal cells, to closely mimic a lymph node environment.
Our key innovations supply sound pharmacology using real CLL patient samples.
Moreover, we can also design specific assays to combine your drug with other therapeutic agents.
Moreover, we can also design specific assays to combine your drug with other therapeutic agents.
Vivia Biotech Peer-Reviewed Published Data on CLL Proliferation Assays
Our CLL proliferation assays played a pivotal role in elucidating, for the first time, the antiproliferative effects of Idelalisib and Ibrutinib in patients with CLL (www.viviabiotech.com/scientific-publications)
HIGHLIGHTS
- TME's Impact on CLL Cells: The TME plays a crucial role in promoting the survival and proliferation of CLL cells, contributing to disease progression and drug resistance.
- Advanced Ex Vivo Proliferation Assay: Our ex vivo proliferation assay incorporates TME stimuli, providing a more accurate simulation of in vivo interactions. This facilitates high-throughput pharmacological characterization under physiological conditions for anti-proliferative CLL drugs.
- Preventing Resistance with Ex Vivo Assay: Our ex vivo assay allows systematic preclinical testing of various combinations to effectively address potential resistance to BTK or PI3Kδ inhibitors treatment.
- Customized Assays for Drug Combinations: We can customize assays to evaluate the most effective combination for your CLL drug with other therapeutic agents, including those undergoing clinical trials or approved for CLL, such as the recently FDA-approved Pirtobrutinib.
- Versatility for Different Compounds: Our proliferation assay is versatile, examining the effects of compounds like T Cell Engagers or NK Cell Engagers on proliferating cell subsets, either alone or combined with BTK or PI3Kδ inhibitors.
- Real-Time Identification and Separation: Vivia proliferation assay enables high-throughput exploration of drug combinations and real-time identification and separation of proliferating and non-proliferating cells.
- Contribution to Personalized Treatment: Our goal is to contribute to predicting the ex vivo response to single or multiple drugs in each CLL patient requiring treatment.